Rhythm Pharmaceuticals (RYTM) Financials

$64.41 +0.40 (+0.62%)

Closing price 05/5/2025 04:00 PM Eastern

Extended Trading

$65.36 +0.95 (+1.48%)

As of 04:48 AM Eastern

Annual Income Statements for Rhythm Pharmaceuticals

This table shows Rhythm Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-29	-38	-74	-281	-134	-70	-181	-185	-265
Consolidated Net Income / (Loss)	-11	-26	-34	-74	-141	-134	-70	-181	-185	-261
Net Income / (Loss) Continuing Operations	-11	-26	-34	-74	0.00	-134	-70	-182	-184	-258
Total Pre-Tax Income	-11	-26	-34	-74	-281	-134	-70	-181	-184	-260
Total Operating Income	-11	-26	-32	-78	-146	-137	-170	-179	-184	-266
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	2.56	22	68	117
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	3.15	24	77	130
Operating Revenue	-	-	-	-	0.00	0.00	3.15	24	77	130
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.60	2.13	9.30	13
Operating Cost of Revenue	-	-	-	-	0.00	0.00	0.60	2.13	9.30	13
Total Operating Expenses	11	26	32	78	292	137	173	201	252	382
Selling, General & Admin Expense	3.43	6.31	9.52	28	37	46	68	92	118	144
Research & Development Expense	7.15	20	23	50	109	90	104	109	135	238
Total Other Income / (Expense), net	-0.50	0.03	-1.30	4.35	11	2.58	100	-1.17	0.05	3.01
Interest Expense	-	-	-	-	-	0.00	0.00	5.20	14	21
Interest & Investment Income	0.00	0.03	0.57	4.35	5.27	2.58	0.45	4.03	14	15
Other Income / (Expense), net	-0.50	0.00	-1.86	-	5.27	0.00	100	0.00	0.00	8.90
Income Tax Expense	-	-	-	-	-	-	0.00	0.00	0.56	0.35
Other Gains / (Losses), net	-	-	-	-	-	-	-	-0.79	0.19	2.24
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	0.00	0.00	3.97
Basic Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	($3.86)	($3.04)	($1.40)	($3.47)	($3.20)	($4.34)
Weighted Average Basic Shares Outstanding	10.20M	10.20M	13.27M	31.00M	36.42M	44.13M	49.60M	52.12M	57.67M	61.00M
Diluted Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	($3.86)	($3.04)	($1.40)	$0.00	($3.20)	($4.34)
Weighted Average Diluted Shares Outstanding	10.20M	10.20M	13.27M	31.00M	36.42M	44.13M	49.60M	0.00	57.67M	61.00M
Weighted Average Basic & Diluted Shares Outstanding	10.20M	10.20M	13.27M	31.00M	36.42M	44.13M	49.60M	56.75M	60.14M	63.22M

This table shows Rhythm Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-41	-42	-52	-47	-44	-42	-141	-34	-45	-45
Consolidated Net Income / (Loss)	-41	-42	-52	-47	-44	-42	-141	-32	-44	-43
Net Income / (Loss) Continuing Operations	-41	-43	-52	-47	-44	-41	-141	-32	-44	-41
Total Pre-Tax Income	-41	-42	-52	-47	-44	-41	-141	-32	-44	-43
Total Operating Income	-39	-42	-53	-47	-44	-41	-140	-40	-44	-41
Total Gross Profit	3.79	7.76	10	17	20	21	23	26	29	38
Total Revenue	4.28	8.79	11	19	23	24	26	29	33	42
Operating Revenue	4.28	8.79	11	19	23	24	26	29	33	42
Total Cost of Revenue	0.50	1.03	1.42	2.24	2.41	3.23	2.81	2.95	3.83	3.79
Operating Cost of Revenue	0.50	1.03	1.42	2.24	2.41	3.23	2.81	2.95	3.83	3.79
Total Operating Expenses	43	50	63	64	64	62	163	67	73	79
Selling, General & Admin Expense	22	26	25	30	30	32	34	36	35	38
Research & Development Expense	21	24	38	34	34	30	129	30	38	41
Total Other Income / (Expense), net	-1.59	0.40	0.35	-0.10	0.16	-0.36	-1.19	8.70	-0.10	-4.40
Interest Expense	2.14	3.01	3.06	3.30	3.15	4.38	4.76	4.60	5.24	6.00
Interest & Investment Income	0.92	2.68	3.44	3.22	3.47	3.82	3.05	4.10	4.05	3.51
Other Income / (Expense), net	-0.37	0.74	-0.03	-0.02	-0.16	0.20	0.52	9.20	1.09	-1.91
Income Tax Expense	0.00	-	0.00	0.00	0.37	0.20	0.30	0.48	-0.34	-0.09
Basic Earnings per Share	($0.79)	($0.74)	($0.92)	($0.82)	($0.76)	($0.70)	($2.35)	($0.55)	($0.73)	($0.71)
Weighted Average Basic Shares Outstanding	51.40M	52.12M	56.71M	56.87M	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M
Weighted Average Diluted Shares Outstanding	51.40M	0.00	56.85M	56.87M	57.87M	57.67M	60.97M	61.01M	61.22M	61.00M
Weighted Average Basic & Diluted Shares Outstanding	56.35M	56.75M	56.85M	56.90M	59.10M	60.14M	60.97M	61.13M	61.46M	63.22M

This table details how cash moves in and out of Rhythm Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	35	-28	28	15	13	39	-42	68	-68	29
Net Cash From Operating Activities	-6.98	-23	-29	-62	-123	-122	-146	-173	-136	-114
Net Cash From Continuing Operating Activities	-6.98	-23	-29	-62	-123	-122	-146	-173	-136	-114
Net Income / (Loss) Continuing Operations	-11	-26	-34	-74	-141	-134	-70	-181	-185	-261
Consolidated Net Income / (Loss)	-11	-26	-34	-74	-141	-134	-70	-181	-185	-261
Depreciation Expense	0.00	0.14	0.22	0.44	0.83	0.69	1.16	1.67	1.76	1.56
Amortization Expense	-	-	-	-	-	0.00	0.00	-2.31	-9.84	-8.17
Non-Cash Adjustments To Reconcile Net Income	1.72	1.31	4.07	11	13	17	-79	26	52	144
Changes in Operating Assets and Liabilities, net	2.38	1.20	-0.04	0.67	4.13	-5.90	1.90	-18	4.62	9.16
Net Cash From Investing Activities	-0.02	-5.11	-110	-87	-28	159	-62	28	-5.67	-48
Net Cash From Continuing Investing Activities	-0.02	-5.11	-110	-87	-28	159	-62	28	-5.67	-48
Purchase of Property, Plant & Equipment	-0.02	-1.06	-0.13	-0.72	-3.39	-0.21	-0.43	-0.28	-0.05	0.00
Acquisitions	-	-	-	-	-	-	0.00	0.00	-5.67	-41
Purchase of Investments	0.00	-15	-127	-249	-296	-87	-525	-252	-355	-268
Sale and/or Maturity of Investments	0.00	11	17	162	271	246	361	284	355	261
Other Investing Activities, net	-	-	-	-	-	0.00	95	-4.00	0.00	0.00
Net Cash From Financing Activities	42	0.00	167	165	163	2.01	166	214	74	191
Net Cash From Continuing Financing Activities	42	0.00	167	165	163	2.01	166	214	74	191
Repayment of Debt	-	-	-	-	-	-	0.00	0.00	-7.40	-13
Issuance of Debt	-	-	-	-	-	0.00	0.00	72	24	0.00
Issuance of Preferred Equity	40	0.00	0.70	-	-	-	-	0.00	0.00	139
Issuance of Common Equity	0.00	0.00	126	163	162	0.52	162	132	50	40
Other Financing Activities, net	2.09	0.00	41	1.81	1.56	1.49	4.13	9.75	7.47	25
Effect of Exchange Rate Changes	-	-	-	-	-	-	0.00	0.00	-0.14	0.00

This table details how cash moves in and out of Rhythm Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	72	-57	-18	6.02	-51	-4.51	-6.52	108	-114	42
Net Cash From Operating Activities	-47	-34	-36	-41	-29	-29	-41	-29	-25	-19
Net Cash From Continuing Operating Activities	-47	-34	-36	-41	-29	-29	-41	-29	-25	-19
Net Income / (Loss) Continuing Operations	-41	-42	-52	-47	-44	-42	-141	-32	-44	-43
Consolidated Net Income / (Loss)	-41	-42	-52	-47	-44	-42	-141	-32	-44	-43
Depreciation Expense	0.44	0.44	0.46	0.44	0.44	0.42	0.41	0.39	0.39	0.38
Amortization Expense	2.14	-4.50	0.72	-5.02	4.30	-9.84	1.95	-5.52	-2.47	-2.14
Non-Cash Adjustments To Reconcile Net Income	5.77	11	12	15	12	13	101	11	16	16
Changes in Operating Assets and Liabilities, net	-14	1.95	2.70	-5.25	-1.71	8.87	-2.68	-2.45	4.19	10
Net Cash From Investing Activities	-40	-41	18	48	-95	23	30	-8.56	-91	21
Net Cash From Continuing Investing Activities	-40	-41	18	48	-95	23	30	-8.56	-91	21
Purchase of Investments	-101	-100	-70	-75	-169	-41	0.00	-66	-136	-66
Sale and/or Maturity of Investments	61	60	93	125	75	63	70	58	45	88
Net Cash From Financing Activities	159	17	-0.13	-0.97	73	2.42	4.24	146	2.49	38
Net Cash From Continuing Financing Activities	159	17	-0.13	-0.97	73	2.42	4.24	146	2.49	38
Repayment of Debt	-	-	-1.35	-1.31	-2.17	-2.57	-2.78	-2.97	-3.34	-3.81
Issuance of Common Equity	117	14	0.67	-	49	-	0.67	-	0.60	39
Other Financing Activities, net	3.86	5.89	0.55	0.34	1.58	5.00	6.35	10	5.23	2.99
Effect of Exchange Rate Changes	-	-	0.09	-0.11	0.08	-0.19	-0.07	-0.30	-0.60	0.98

This table presents Rhythm Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	12	152	309	187	330	382	333	392
Total Current Assets	11	151	302	182	308	354	308	374
Cash & Equivalents	6.54	34	62	101	59	128	60	89
Restricted Cash	-	-	-	-	-	-	-	0.46
Short-Term Investments	4.00	114	230	72	236	206	216	231
Accounts Receivable	-	-	-	-	1.03	6.22	15	19
Inventories, net	-	-	-	-	0.11	2.92	8.62	19
Prepaid Expenses	0.64	2.59	9.95	8.88	12	12	8.93	16
Plant, Property, & Equipment, net	0.93	0.84	3.67	3.20	2.81	2.20	1.34	0.63
Total Noncurrent Assets	0.23	0.23	2.45	2.21	18	26	23	17
Long-Term Investments	-	-	-	-	12	17	15	7.33
Intangible Assets	-	-	-	0.00	4.66	7.88	7.03	6.17
Other Noncurrent Operating Assets	0.23	0.23	2.45	2.21	1.85	1.51	1.11	3.48
Total Liabilities & Shareholders' Equity	12	152	309	187	330	382	333	392
Total Liabilities	5.04	6.95	28	21	45	118	163	228
Total Current Liabilities	4.73	6.72	24	18	43	40	55	116
Short-Term Debt	-	-	-	-	-	-	0.00	1.54
Accounts Payable	2.00	2.43	10	4.90	5.74	4.80	4.89	12
Accrued Expenses	2.66	4.21	14	13	30	33	48	63
Current Deferred Revenue	0.08	0.08	-	-	7.00	1.43	1.29	1.29
Other Current Liabilities	-	-	0.47	0.54	0.61	0.68	0.77	38
Total Noncurrent Liabilities	0.31	0.23	3.09	2.55	1.95	78	108	112
Long-Term Debt	-	-	-	-	-	-	106	108
Other Noncurrent Operating Liabilities	-	-	3.09	2.55	1.95	2.60	1.64	3.94
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	-	0.00	0.00
Redeemable Noncontrolling Interest	40	0.00	-	-	-	-	0.00	143
Total Equity & Noncontrolling Interests	-33	145	281	167	284	264	170	22
Total Preferred & Common Equity	-33	145	281	167	284	264	170	22
Total Common Equity	-33	145	281	167	284	264	170	22
Common Stock	44	255	606	626	813	974	1,064	1,177
Retained Earnings	-77	-110	-325	-459	-529	-710	-895	-1,155
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	0.05	-0.00	-0.09	0.13	-0.04

This table presents Rhythm Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	390	346	310	354	259	382	364
Total Current Assets	362	318	284	329	236	357	340
Cash & Equivalents	185	110	116	65	53	162	48
Restricted Cash	-	-	-	-	-	0.46	0.46
Short-Term Investments	163	185	138	235	148	157	251
Accounts Receivable	3.33	8.12	14	15	15	18	19
Inventories, net	-	5.49	6.18	7.76	8.51	12	14
Prepaid Expenses	11	9.65	10	7.64	11	8.64	8.75
Plant, Property, & Equipment, net	2.43	2.00	1.77	1.55	1.15	0.97	0.80
Total Noncurrent Assets	25	26	24	23	22	23	22
Long-Term Investments	16	17	16	15	14	13	12
Intangible Assets	8.10	7.67	7.46	7.24	6.82	6.60	6.39
Other Noncurrent Operating Assets	1.60	1.42	1.32	1.22	1.13	3.70	3.59
Total Liabilities & Shareholders' Equity	390	346	310	354	259	382	364
Total Liabilities	108	126	128	157	197	202	211
Total Current Liabilities	33	46	46	50	54	55	98
Accounts Payable	4.93	13	8.38	3.84	7.55	4.54	4.89
Accrued Expenses	26	31	36	44	45	48	55
Current Deferred Revenue	1.76	1.43	1.29	1.29	1.29	1.29	1.29
Other Current Liabilities	0.66	0.71	0.73	0.75	0.79	1.18	37
Total Noncurrent Liabilities	75	80	82	107	143	147	113
Noncurrent Deferred Revenue	-	78	79	105	107	108	109
Other Noncurrent Operating Liabilities	2.36	2.37	2.21	1.88	36	39	4.03
Commitments & Contingencies	-	-	-	-	-	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	140	141
Total Equity & Noncontrolling Interests	281	220	182	197	62	39	11
Total Preferred & Common Equity	281	220	182	197	62	39	11
Preferred Stock	-	-	-	-	-	0.00	0.00
Total Common Equity	281	220	182	197	62	39	11
Common Stock	949	982	991	1,051	1,098	1,108	1,124
Retained Earnings	-668	-762	-809	-853	-1,036	-1,068	-1,112
Accumulated Other Comprehensive Income / (Loss)	-0.34	-0.01	-0.01	-0.11	-0.18	-0.62	-0.60

This table displays calculated financial ratios and metrics derived from Rhythm Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	649.46%	227.56%	68.06%
EBITDA Growth	0.00%	-132.65%	-32.18%	-128.99%	-79.41%	2.87%	49.29%	-160.95%	-7.03%	-36.78%
EBIT Growth	0.00%	-133.95%	-32.31%	-128.79%	-79.46%	2.95%	48.70%	-155.72%	-2.90%	-39.19%
NOPAT Growth	0.00%	-145.01%	-25.12%	-141.94%	-86.18%	6.46%	-24.52%	-5.35%	-2.90%	-44.02%
Net Income Growth	0.00%	-133.65%	-30.29%	-119.72%	-90.01%	4.78%	48.05%	-160.18%	-1.97%	-41.11%
EPS Growth	0.00%	-141.53%	0.70%	15.55%	-61.51%	21.24%	53.95%	100.00%	0.00%	-35.63%
Operating Cash Flow Growth	0.00%	-232.79%	-26.88%	-110.64%	-97.81%	0.63%	-19.69%	-18.78%	21.49%	16.36%
Free Cash Flow Firm Growth	0.00%	0.00%	-52.13%	-156.97%	-55.98%	-11.04%	-1.99%	39.44%	-220.96%	26.52%
Invested Capital Growth	0.00%	0.00%	-1.39%	100.00%	0.00%	45.24%	-259.50%	-280.48%	82.56%	-261.35%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	135.90%	41.84%	24.92%	15.64%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-25.85%	-16,423.80%	-19,429.30%	-29.68%	2.83%	-5.28%	-3.13%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-25.97%	0.00%	0.00%	-29.40%	5.10%	0.59%	-0.90%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-25.97%	0.00%	0.00%	-10.33%	4.73%	0.45%	0.01%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-25.35%	0.00%	0.00%	-12.93%	0.21%	0.46%	-0.65%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-106.03%	0.00%	0.00%	-9.38%	100.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-6.15%	-26.75%	-10.08%	2.48%	-8.43%	3.60%	3.28%	8.47%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-1,285.64%	-1,713.52%	-6.93%	55.22%	-803.70%	-1.59%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	100.00%	-9.95%	-29.23%	-35.46%	-825.78%	87.20%	65.86%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	81.01%	90.98%	87.99%	89.73%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,184.56%	-760.64%	-248.53%	-202.27%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,391.85%	-757.92%	-238.10%	-204.04%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,221.27%	-757.92%	-238.10%	-197.20%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,207.10%	-766.22%	-238.52%	-200.27%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	50.00%	100.00%	100.00%	100.00%	100.31%	100.13%
Interest Burden Percent	100.00%	99.87%	98.35%	94.45%	200.00%	98.11%	99.36%	101.10%	99.87%	101.42%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-354.56%	-44.33%	-102.31%	-100.16%	-59.88%	-30.89%	-66.05%	-85.10%	-155.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-27.12%	-50.32%	-51.55%	-70.79%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-26.95%	-50.88%	-51.64%	-71.89%
Return on Common Equity (ROCE)	0.00%	1,589.02%	-32.67%	-102.31%	-100.16%	-59.88%	-30.89%	-66.05%	-85.10%	-89.30%
Return on Equity Simple (ROE_SIMPLE)	0.00%	79.11%	-23.28%	0.00%	-50.08%	-80.46%	-24.50%	-68.54%	-108.79%	-1,199.33%
Net Operating Profit after Tax (NOPAT)	-7.40	-18	-23	-55	-102	-96	-119	-125	-129	-186
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,774.30%	-530.54%	-166.67%	-142.82%
Net Nonoperating Expense Percent (NNEP)	0.00%	-146.76%	-13.89%	-25.89%	-26.35%	-16.50%	20.62%	-16.97%	-20.81%	-37.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-47.46%	-46.77%	-141.29%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18.99%	9.02%	12.01%	10.27%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,171.40%	389.34%	151.80%	110.90%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,301.46%	459.56%	174.29%	182.87%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5,472.86%	848.90%	326.09%	293.76%
Earnings before Interest and Taxes (EBIT)	-11	-26	-34	-78	-141	-137	-70	-179	-184	-257
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-26	-34	-78	-140	-136	-69	-180	-192	-263
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.48	0.00	3.59	7.89	1.77	6.21	16.00	158.33
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.48	0.00	3.59	7.89	1.80	6.40	16.69	221.17
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	159.06	69.42	35.09	26.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	61.83	54.61	32.70	25.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.67
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.66
Financial Leverage	0.00	-1.45	-1.04	-1.02	-1.04	-1.04	-1.06	-1.20	-1.23	-1.21
Leverage Ratio	0.00	1.69	1.08	1.05	1.10	1.11	1.15	1.30	1.65	2.17
Compound Leverage Factor	0.00	1.69	1.06	0.99	2.20	1.09	1.14	1.31	1.65	2.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.47%	40.02%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.56%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.47%	39.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	548.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	52.06%
Common Equity to Total Capital	0.00%	-448.17%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	61.53%	7.92%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.55	-0.42
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.96	0.83
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.55	-0.41
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.82	-0.59
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.43	1.18
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.82	-0.58
Altman Z-Score	0.00	0.00	67.85	0.00	20.10	33.58	4.66	5.23	5.55	3.91
Noncontrolling Interest Sharing Ratio	0.00%	548.17%	26.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	42.72%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	2.36	22.42	0.00	12.39	10.10	7.10	8.90	5.58	3.24
Quick Ratio	0.00	2.23	22.04	0.00	11.98	9.60	6.81	8.53	5.27	2.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-15	-23	-58	-91	-101	-103	-62	-200	-147
Operating Cash Flow to CapEx	-41,041.18%	-2,196.69%	-22,150.38%	-8,595.01%	-3,626.29%	-57,000.00%	-33,641.24%	-61,718.15%	-289,695.74%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-11.97	-14.38	-7.13
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.35	-9.80	-5.53
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.40	-9.80	-5.53
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.07	0.22	0.36
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.52	7.34	7.80
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.41	1.61	0.98
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	1.05	9.44	43.77	131.91
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.41	1.92	1.55
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55.97	49.71	46.81
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	259.08	226.43	373.59
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	3,240.82	901.29	189.96	234.99
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	-3,240.82	-586.25	86.18	185.41
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-3.25	-3.29	0.00	-11	-6.26	-23	-86	-15	-54
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	-0.22	-0.44	-1.54	-3.78
Increase / (Decrease) in Invested Capital	0.00	-3.25	-0.05	3.29	-11	5.18	-16	-63	71	-39
Enterprise Value (EV)	0.00	0.00	645	925	716	1,141	195	1,291	2,532	3,365
Market Capitalization	0.00	0.00	793	925	1,009	1,314	502	1,641	2,717	3,440
Book Value per Share	$0.00	($3.21)	$5.31	$0.00	$6.40	$3.77	$5.65	$4.69	$2.87	$0.35
Tangible Book Value per Share	$0.00	($3.21)	$5.31	$0.00	$6.40	$3.77	$5.56	$4.55	$2.75	$0.25
Total Capital	0.00	7.30	145	0.00	281	167	284	264	276	274
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	106	110
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	106	108
Net Debt	0.00	-11	-148	0.00	-292	-173	-307	-350	-185	-219
Capital Expenditures (CapEx)	0.02	1.06	0.13	0.72	3.39	0.21	0.43	0.28	0.05	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-4.09	-4.13	0.00	-14	-9.12	-30	-19	-23	-61
Debt-free Net Working Capital (DFNWC)	0.00	6.44	144	0.00	278	164	265	314	253	260
Net Working Capital (NWC)	0.00	6.44	144	0.00	278	164	265	314	253	259
Net Nonoperating Expense (NNE)	3.67	7.74	11	19	39	38	-49	56	56	75
Net Nonoperating Obligations (NNO)	0.00	-11	-148	0.00	-292	-173	-307	-350	-185	-219
Total Depreciation and Amortization (D&A)	0.00	0.14	0.22	0.44	0.83	0.69	1.16	-0.64	-8.08	-6.60
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-947.84%	-79.79%	-29.42%	-46.73%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,400.76%	1,330.18%	326.84%	199.98%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,400.76%	1,330.18%	326.84%	198.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	$0.00	($3.04)	($1.40)	($3.47)	($3.20)	($4.34)
Adjusted Weighted Average Basic Shares Outstanding	10.20M	10.20M	27.28M	34.43M	0.00	50.18M	49.60M	52.12M	57.67M	61.00M
Adjusted Diluted Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	$0.00	($3.04)	($1.40)	($3.47)	($3.20)	($4.34)
Adjusted Weighted Average Diluted Shares Outstanding	10.20M	10.20M	27.28M	34.43M	0.00	50.18M	49.60M	52.12M	57.67M	61.00M
Adjusted Basic & Diluted Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	$0.00	($3.04)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	10.20M	10.20M	13.27M	31.00M	0.00	44.13M	49.60M	56.75M	60.14M	63.22M
Normalized Net Operating Profit after Tax (NOPAT)	-7.40	-18	-23	-55	-102	-96	-119	-125	-129	-186
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,774.30%	-530.54%	-166.67%	-142.82%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,207.10%	-766.22%	-237.79%	-200.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-34.45	-13.27	-12.45
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-24.11	-9.29	-9.02
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-34.50	-13.27	-12.45
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-24.17	-9.29	-9.02
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Rhythm Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	316.73%	383.76%	665.62%	112.01%	425.30%	175.70%	126.41%	51.28%	47.76%	72.61%
EBITDA Growth	15.65%	10.33%	2.27%	-14.42%	-6.26%	-11.13%	-166.64%	28.90%	-13.98%	11.02%
EBIT Growth	10.40%	18.87%	0.69%	-3.08%	-11.29%	0.73%	-165.16%	32.91%	2.98%	-5.12%
NOPAT Growth	11.24%	17.43%	0.30%	-3.34%	-11.93%	1.98%	-166.29%	13.14%	0.15%	0.04%
Net Income Growth	-16.39%	0.87%	1.11%	-3.78%	-8.08%	2.02%	-170.94%	30.92%	1.18%	-4.07%
EPS Growth	-12.86%	403.33%	0.00%	7.87%	3.80%	0.00%	0.00%	32.93%	3.95%	0.00%
Operating Cash Flow Growth	-17.00%	15.99%	32.07%	-5.88%	37.75%	13.58%	-11.83%	29.24%	13.80%	35.86%
Free Cash Flow Firm Growth	-81.63%	273.33%	184.15%	223.28%	320.22%	-395.72%	-215.43%	15.11%	-86.13%	110.21%
Invested Capital Growth	44.33%	-280.48%	-288.83%	-304.24%	-1,161.82%	82.56%	-67.54%	-76.02%	-35.42%	-261.35%
Revenue Q/Q Growth	-52.75%	105.18%	30.48%	67.59%	17.08%	7.69%	7.15%	11.98%	14.35%	25.80%
EBITDA Q/Q Growth	17.20%	-22.61%	-25.84%	0.36%	23.10%	-28.23%	-196.06%	73.43%	-23.28%	-0.10%
EBIT Q/Q Growth	12.36%	-4.36%	-24.67%	11.30%	5.38%	6.91%	-240.94%	77.56%	-36.84%	-0.86%
NOPAT Q/Q Growth	12.93%	-7.22%	-24.77%	11.28%	5.69%	6.11%	-238.96%	71.06%	-8.42%	6.00%
Net Income Q/Q Growth	9.20%	-3.99%	-22.79%	10.49%	5.44%	5.73%	-239.57%	77.18%	-35.27%	0.72%
EPS Q/Q Growth	11.24%	445.57%	0.00%	0.00%	7.32%	0.00%	0.00%	0.00%	-32.73%	0.00%
Operating Cash Flow Q/Q Growth	-21.07%	27.64%	-7.16%	-12.78%	28.81%	-0.45%	-38.66%	28.64%	13.28%	25.26%
Free Cash Flow Firm Q/Q Growth	-31.28%	196.65%	-7.24%	4.74%	134.51%	-229.79%	-653.53%	204.45%	-71.74%	-4.43%
Invested Capital Q/Q Growth	56.92%	-825.78%	-6.88%	5.17%	-34.49%	87.20%	-26.71%	0.38%	-3.47%	65.86%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.40%	88.30%	87.61%	88.37%	89.28%	86.66%	89.19%	89.87%	88.49%	90.95%
EBITDA Margin	-864.87%	-516.83%	-448.00%	-266.36%	-174.95%	-208.32%	-527.61%	-125.19%	-134.96%	-107.39%
Operating Margin	-916.60%	-478.99%	-458.03%	-242.46%	-195.31%	-170.29%	-538.71%	-139.20%	-131.98%	-98.62%
EBIT Margin	-925.23%	-470.61%	-458.26%	-242.55%	-196.02%	-169.46%	-536.69%	-107.56%	-128.71%	-103.20%
Profit (Net Income) Margin	-953.80%	-483.42%	-454.96%	-242.98%	-196.25%	-171.80%	-544.43%	-110.95%	-131.25%	-103.58%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.84%	100.47%	100.21%	101.51%	99.22%	99.80%
Interest Burden Percent	103.09%	102.72%	99.28%	100.18%	99.28%	100.90%	101.23%	101.62%	102.78%	100.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-60.15%	-66.05%	-79.26%	-96.44%	-77.52%	-85.10%	-194.69%	-143.42%	-147.88%	-155.91%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-41.37%	-31.25%	-48.86%	-36.13%	-32.67%	-36.69%	-163.28%	-31.65%	-40.36%	-37.04%
Return on Assets (ROA)	-42.65%	-32.10%	-48.50%	-36.19%	-32.71%	-37.20%	-165.63%	-32.65%	-41.15%	-37.18%
Return on Common Equity (ROCE)	-60.15%	-66.05%	-79.26%	-96.44%	-77.52%	-85.10%	-194.69%	-87.86%	-88.13%	-89.30%
Return on Equity Simple (ROE_SIMPLE)	-64.54%	0.00%	-82.15%	-99.97%	-93.96%	0.00%	-444.73%	-659.40%	-2,308.58%	0.00%
Net Operating Profit after Tax (NOPAT)	-27	-29	-37	-33	-31	-29	-98	-28	-31	-29
NOPAT Margin	-641.62%	-335.29%	-320.62%	-169.72%	-136.72%	-119.21%	-377.10%	-97.44%	-92.39%	-69.03%
Net Nonoperating Expense Percent (NNEP)	-4.25%	-3.97%	-5.40%	-5.79%	-4.43%	-4.77%	-16.51%	-1.31%	-4.13%	-7.17%
Return On Investment Capital (ROIC_SIMPLE)	-	-11.15%	-	-	-	-10.47%	-	-	-	-21.95%
Cost of Revenue to Revenue	11.60%	11.70%	12.39%	11.63%	10.72%	13.34%	10.81%	10.13%	11.51%	9.05%
SG&A Expenses to Revenue	512.09%	299.40%	214.79%	156.32%	135.42%	133.60%	132.41%	125.23%	106.39%	91.15%
R&D to Revenue	492.90%	267.90%	330.85%	174.51%	149.17%	123.35%	495.49%	103.84%	114.07%	98.42%
Operating Expenses to Revenue	1,005.00%	567.29%	545.64%	330.83%	284.59%	256.95%	627.90%	229.07%	220.47%	189.57%
Earnings before Interest and Taxes (EBIT)	-40	-41	-53	-47	-44	-41	-139	-31	-43	-43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-37	-45	-51	-51	-39	-50	-137	-36	-45	-45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.42	6.21	4.61	5.14	6.61	16.00	42.32	63.63	285.58	158.33
Price to Tangible Book Value (P/TBV)	4.55	6.40	4.77	5.36	6.86	16.69	47.58	76.46	663.52	221.17
Price to Revenue (P/Rev)	74.57	69.42	30.12	21.42	21.05	35.09	28.35	24.60	28.46	26.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	57.14	54.61	20.86	15.27	15.98	32.70	26.01	22.71	26.96	25.86
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.26	0.00	0.00	0.00	0.00	0.63	0.00	0.00	0.00	0.67
Long-Term Debt to Equity	0.26	0.00	0.00	0.00	0.00	0.63	0.00	0.00	0.00	0.66
Financial Leverage	-1.04	-1.20	-1.25	-1.29	-1.26	-1.23	-1.87	-1.66	-1.79	-1.21
Leverage Ratio	1.24	1.30	1.38	1.55	1.55	1.65	2.15	1.91	2.05	2.17
Compound Leverage Factor	1.27	1.33	1.37	1.56	1.54	1.66	2.17	1.94	2.11	2.18
Debt to Total Capital	20.60%	0.00%	0.00%	0.00%	0.00%	38.47%	0.00%	0.00%	0.00%	40.02%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.56%
Long-Term Debt to Total Capital	20.60%	0.00%	0.00%	0.00%	0.00%	38.47%	0.00%	0.00%	0.00%	39.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	78.08%	92.66%	52.06%
Common Equity to Total Capital	79.40%	100.00%	100.00%	100.00%	100.00%	61.53%	100.00%	21.92%	7.34%	7.92%
Debt to EBITDA	-0.39	0.00	0.00	0.00	0.00	-0.55	0.00	0.00	0.00	-0.42
Net Debt to EBITDA	1.57	0.00	0.00	0.00	0.00	0.96	0.00	0.00	0.00	0.83
Long-Term Debt to EBITDA	-0.39	0.00	0.00	0.00	0.00	-0.55	0.00	0.00	0.00	-0.41
Debt to NOPAT	-0.55	0.00	0.00	0.00	0.00	-0.82	0.00	0.00	0.00	-0.59
Net Debt to NOPAT	2.21	0.00	0.00	0.00	0.00	1.43	0.00	0.00	0.00	1.18
Long-Term Debt to NOPAT	-0.55	0.00	0.00	0.00	0.00	-0.82	0.00	0.00	0.00	-0.58
Altman Z-Score	5.20	6.42	2.28	1.32	2.33	6.97	1.75	4.45	5.55	5.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.74%	40.40%	42.72%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.93	8.90	6.91	6.16	6.57	5.58	4.35	6.53	3.49	3.24
Quick Ratio	10.61	8.53	6.58	5.80	6.26	5.27	3.99	6.15	3.25	2.94
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-35	34	31	33	77	-100	-36	38	11	10
Operating Cash Flow to CapEx	-49,460.00%	0.00%	-77,517.02%	0.00%	-2,925,100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-16.26	11.19	10.21	9.91	24.38	-22.75	-7.59	8.19	2.03	1.70
Operating Cash Flow to Interest Expense	-21.92	-11.29	-11.90	-12.44	-9.29	-6.71	-8.57	-6.32	-4.81	-3.14
Operating Cash Flow Less CapEx to Interest Expense	-21.96	-11.29	-11.92	-12.44	-9.29	-6.71	-8.57	-6.32	-4.81	-3.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.07	0.11	0.15	0.17	0.22	0.30	0.29	0.31	0.36
Accounts Receivable Turnover	0.00	6.52	7.49	5.63	6.94	7.34	8.06	6.48	6.65	7.80
Inventory Turnover	0.00	1.41	0.00	0.00	0.00	1.61	1.53	1.25	1.18	0.98
Fixed Asset Turnover	6.19	9.44	14.23	20.21	31.22	43.77	58.37	74.13	95.93	131.91
Accounts Payable Turnover	0.28	0.41	0.26	0.72	1.62	1.92	1.02	1.76	2.94	1.55
Days Sales Outstanding (DSO)	0.00	55.97	48.76	64.79	52.61	49.71	45.29	56.35	54.89	46.81
Days Inventory Outstanding (DIO)	0.00	259.08	0.00	0.00	0.00	226.43	238.95	290.94	308.42	373.59
Days Payable Outstanding (DPO)	1,299.27	901.29	1,392.19	506.96	225.57	189.96	356.82	206.95	124.27	234.99
Cash Conversion Cycle (CCC)	-1,299.27	-586.25	-1,343.44	-442.17	-172.96	86.18	-72.58	140.34	239.04	185.41
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-9.26	-86	-92	-87	-117	-15	-153	-153	-158	-54
Invested Capital Turnover	-1.29	-0.44	-0.58	-0.81	-0.98	-1.54	-0.75	-0.85	-0.82	-3.78
Increase / (Decrease) in Invested Capital	7.37	-63	-68	-65	-108	71	-62	-66	-41	-39
Enterprise Value (EV)	952	1,291	701	668	990	2,532	2,391	2,311	3,033	3,365
Market Capitalization	1,243	1,641	1,012	938	1,304	2,717	2,606	2,504	3,203	3,440
Book Value per Share	$5.54	$4.69	$3.87	$3.21	$3.47	$2.87	$1.02	$0.65	$0.18	$0.35
Tangible Book Value per Share	$5.38	$4.55	$3.74	$3.08	$3.34	$2.75	$0.91	$0.54	$0.08	$0.25
Total Capital	354	264	220	182	197	276	62	179	153	274
Total Debt	73	0.00	0.00	0.00	0.00	106	0.00	0.00	0.00	110
Total Long-Term Debt	73	0.00	0.00	0.00	0.00	106	0.00	0.00	0.00	108
Net Debt	-290	-350	-311	-269	-314	-185	-215	-332	-311	-219
Capital Expenditures (CapEx)	0.10	-0.00	0.05	0.00	0.00	-0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-19	-23	-16	-20	-23	-20	-17	-56	-61
Debt-free Net Working Capital (DFNWC)	329	314	272	238	279	253	182	303	243	260
Net Working Capital (NWC)	329	314	272	238	279	253	182	303	243	259
Net Nonoperating Expense (NNE)	13	13	15	14	13	13	43	3.93	13	14
Net Nonoperating Obligations (NNO)	-290	-350	-311	-269	-314	-185	-215	-332	-311	-219
Total Depreciation and Amortization (D&A)	2.59	-4.06	1.18	-4.58	4.74	-9.42	2.36	-5.13	-2.08	-1.76
Debt-free, Cash-free Net Working Capital to Revenue	-114.13%	-79.79%	-67.76%	-36.16%	-32.59%	-29.42%	-21.33%	-16.65%	-49.87%	-46.73%
Debt-free Net Working Capital to Revenue	1,972.85%	1,330.18%	808.74%	543.31%	450.21%	326.84%	197.54%	297.34%	215.71%	199.98%
Net Working Capital to Revenue	1,972.85%	1,330.18%	808.74%	543.31%	450.21%	326.84%	197.54%	297.34%	215.71%	198.79%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.79)	($0.74)	($0.92)	($0.82)	($0.76)	($0.70)	($2.35)	($0.55)	($0.73)	($0.71)
Adjusted Weighted Average Basic Shares Outstanding	51.40M	52.12M	56.71M	56.87M	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M
Adjusted Diluted Earnings per Share	($0.79)	$2.73	($0.92)	($0.82)	($0.76)	$0.00	$0.00	($0.55)	($0.73)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	51.40M	0.00	56.71M	56.87M	57.87M	57.67M	60.97M	61.01M	61.22M	61.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	56.35M	56.75M	56.85M	56.90M	59.10M	60.14M	60.97M	61.13M	61.46M	63.22M
Normalized Net Operating Profit after Tax (NOPAT)	-27	-29	-37	-33	-31	-29	-98	-28	-31	-29
Normalized NOPAT Margin	-641.62%	-335.29%	-320.62%	-169.72%	-136.72%	-119.21%	-377.10%	-97.44%	-92.39%	-69.03%
Pre Tax Income Margin	-953.80%	-483.42%	-454.96%	-242.98%	-194.61%	-170.99%	-543.27%	-109.30%	-132.28%	-103.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-18.49	-13.74	-17.17	-14.11	-14.01	-9.38	-29.31	-6.79	-8.16	-7.19
NOPAT to Interest Expense	-12.82	-9.79	-12.01	-9.88	-9.77	-6.60	-20.59	-6.16	-5.86	-4.81
EBIT Less CapEx to Interest Expense	-18.53	-13.74	-17.19	-14.11	-14.01	-9.38	-29.31	-6.79	-8.16	-7.19
NOPAT Less CapEx to Interest Expense	-12.86	-9.79	-12.03	-9.88	-9.77	-6.60	-20.59	-6.16	-5.86	-4.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Rhythm Pharmaceuticals' Financials

When does Rhythm Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Rhythm Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Rhythm Pharmaceuticals' net income changed over the last 9 years?

Rhythm Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$260.60 million in 2024, rising from -$11.07 million in 2015. The previous period was -$184.68 million in 2023. See Rhythm Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Rhythm Pharmaceuticals's operating income?

Rhythm Pharmaceuticals's total operating income in 2024 was -$265.50 million, based on the following breakdown:

Total Gross Profit: $116.76 million
Total Operating Expenses: $382.26 million

How has Rhythm Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Rhythm Pharmaceuticals' total revenue changed from $0.00 in 2015 to $130.13 million in 2024, a change of 13,012,600,000.0%.

How much debt does Rhythm Pharmaceuticals have?

Rhythm Pharmaceuticals' total liabilities were at $227.72 million at the end of 2024, a 39.7% increase from 2023, and a 4,416.5% increase since 2016.

How much cash does Rhythm Pharmaceuticals have?

In the past 7 years, Rhythm Pharmaceuticals' cash and equivalents has ranged from $6.54 million in 2016 to $127.68 million in 2022, and is currently $89.14 million as of their latest financial filing in 2024.

How has Rhythm Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Rhythm Pharmaceuticals' book value per share changed from 0.00 in 2015 to 0.35 in 2024, a change of 35.4%.

Related Companies

This page (NASDAQ:RYTM) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Financials

Frequently Asked Questions About Rhythm Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Financials

Annual Income Statements for Rhythm Pharmaceuticals

Quarterly Income Statements for Rhythm Pharmaceuticals

Annual Cash Flow Statements for Rhythm Pharmaceuticals

Quarterly Cash Flow Statements for Rhythm Pharmaceuticals

Annual Balance Sheets for Rhythm Pharmaceuticals

Quarterly Balance Sheets for Rhythm Pharmaceuticals

Annual Metrics and Ratios for Rhythm Pharmaceuticals

Quarterly Metrics and Ratios for Rhythm Pharmaceuticals

Frequently Asked Questions About Rhythm Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools